Cargando…

Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single‐center analysis in Japan

BACKGROUND: The paradigm of medical treatment for metastatic urothelial carcinoma is dramatically changing through the introduction of pembrolizumab. AIM: We investigated the treatment effectiveness, the safety profile, and the prognostic factors of pembrolizumab in Japanese real‐world clinical prac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujiwara, Motohiro, Yuasa, Takeshi, Urasaki, Tetsuya, Komai, Yoshinobu, Fujiwara, Ryo, Numao, Noboru, Yamamoto, Shinya, Yonese, Junji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714548/ https://www.ncbi.nlm.nih.gov/pubmed/33934570 http://dx.doi.org/10.1002/cnr2.1398

Ejemplares similares

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high
por: Fujiwara, Motohiro, et al.
Publicado: (2020)

A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome
por: Oki, Ryosuke, et al.
Publicado: (2022)

The utility of diffusion‐weighted whole‐body imaging with background body signal suppression in detecting metastatic lesion of germ cell carcinoma
por: Yoshitomi, Kasumi Kaneko, et al.
Publicado: (2021)

Unusual metastasis from renal cell cancer after partial nephrectomy and sequential targeted therapy
por: Yasuoka, Shotaro, et al.
Publicado: (2021)

External validation of the Briganti 2019 nomogram to identify candidates for extended pelvic lymph node dissection among patients with high-risk clinically localized prostate cancer
por: Fukagawa, Eri, et al.
Publicado: (2021)

Case Report: A Case of Trimethoprim/Sulfamethoxazole-Triggered Hypotensive Shock: Cytokine Release Syndrome Related to Immune Checkpoint Inhibitors and Drug-Induced Hypersensitivity Syndrome
por: Urasaki, Tetsuya, et al.
Publicado: (2021)

De novo large‐cell neuroendocrine carcinoma of the prostate: A case report and literature review
por: Fukagawa, Eri, et al.
Publicado: (2022)

Biomarkers to predict prognosis and response to checkpoint inhibitors
por: Yuasa, Takeshi, et al.
Publicado: (2017)

Testicular seminoma with a progressing pulmonary nodule and mediastinal lymphadenopathy without retroperitoneal metastasis
por: Sano, Yuta, et al.
Publicado: (2020)

Recent advances in medical therapy for metastatic urothelial cancer
por: Yuasa, Takeshi, et al.
Publicado: (2018)

A case of sequential medical therapy for advanced ureteral cancer in Li–Fraumeni syndrome
por: Une, Minami, et al.
Publicado: (2023)

Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study
por: Fukushima, Hiroshi, et al.
Publicado: (2020)

Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report
por: Sano, Masayuki, et al.
Publicado: (2016)

Denosumab: a new option in the treatment of bone metastases from urological cancers
por: Yuasa, Takeshi, et al.
Publicado: (2012)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer
por: Uehara, Sho, et al.
Publicado: (2015)

Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma
por: Inamura, Kentaro, et al.
Publicado: (2019)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
por: Kamei, Jun, et al.
Publicado: (2022)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis
por: Ishii, Akiko, et al.
Publicado: (2020)

Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
por: Yamasaki, Mutsushi, et al.
Publicado: (2016)

A case of gastric metastasis from renal cell cancer during the sequential targeted therapy
por: Uehara, Sho, et al.
Publicado: (2017)

Recent Advances in Medical Therapy for Urological Cancers
por: Yuasa, Takeshi, et al.
Publicado: (2022)

Therapeutic inhibition of mitochondrial function induces cell death in starvation-resistant renal cell carcinomas
por: Isono, Takahiro, et al.
Publicado: (2016)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report
por: Hasegawa, Moto, et al.
Publicado: (2020)

Early onset recall pneumonitis during targeted therapy with sunitinib
por: Yuasa, Takeshi, et al.
Publicado: (2013)

Comparison Between Dose-Escalated Intensity Modulated Radiation Therapy and 3-Dimensional Conformal Radiation Therapy for Salvage Radiation Therapy After Prostatectomy
por: Shimoyachi, Nana, et al.
Publicado: (2021)

Abundance of TRAIL attenuated by HIF2α and c-FLIP affects malignancy in renal cell carcinomas
por: Isono, Takahiro, et al.
Publicado: (2018)

Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience
por: Crist, Michael, et al.
Publicado: (2019)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
por: Rijnders, Maud, et al.
Publicado: (2022)

A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma
por: Fukiishi, Yousuke, et al.
Publicado: (2022)

A CASE OF RAPIDLY PROGRESSIVE RETINOPATHY ASSOCIATED WITH PEMBROLIZUMAB IMMUNOTHERAPY FOR METASTATIC UROTHELIAL CARCINOMA
por: Sakai, Daiki, et al.
Publicado: (2023)

Clinical outcome of patients with pancreatic metastases from renal cell cancer
por: Yuasa, Takeshi, et al.
Publicado: (2015)

A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab
por: Liu, Yung-Hao, et al.
Publicado: (2021)

Treatment impact of newly approved therapeutic agents for metastatic urothelial carcinoma in Japan: a single-center retrospective study
por: Inoue, Yuta, et al.
Publicado: (2023)

Impact of Serum γ-Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel
por: Une, Minami, et al.
Publicado: (2021)

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
por: Shimizu, Takuto, et al.
Publicado: (2020)

Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma
por: Hamada, Kazuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qljmv9dgmlmgd54374seteatdv